| Literature DB >> 33614648 |
Sabah Nisar1, Ajaz A Bhat1, Mayank Singh2, Thasni Karedath3, Arshi Rizwan4, Sheema Hashem1, Puneet Bagga5, Ravinder Reddy6, Farrukh Jamal7, Shahab Uddin8, Gyan Chand9, Davide Bedognetti10,11,12, Wael El-Rifai13, Michael P Frenneaux14, Muzafar A Macha15, Ikhlak Ahmed3,3, Mohammad Haris1,16.
Abstract
Circular RNAs (circRNAs) are an evolutionarily conserved novel class of non-coding endogenous RNAs (ncRNAs) found in the eukaryotic transcriptome, originally believed to be aberrant RNA splicing by-products with decreased functionality. However, recent advances in high-throughput genomic technology have allowed circRNAs to be characterized in detail and revealed their role in controlling various biological and molecular processes, the most essential being gene regulation. Because of the structural stability, high expression, availability of microRNA (miRNA) binding sites and tissue-specific expression, circRNAs have become hot topic of research in RNA biology. Compared to the linear RNA, circRNAs are produced differentially by backsplicing exons or lariat introns from a pre-messenger RNA (mRNA) forming a covalently closed loop structure missing 3' poly-(A) tail or 5' cap, rendering them immune to exonuclease-mediated degradation. Emerging research has identified multifaceted roles of circRNAs as miRNA and RNA binding protein (RBP) sponges and transcription, translation, and splicing event regulators. CircRNAs have been involved in many human illnesses, including cancer and neurodegenerative disorders such as Alzheimer's and Parkinson's disease, due to their aberrant expression in different pathological conditions. The functional versatility exhibited by circRNAs enables them to serve as potential diagnostic or predictive biomarkers for various diseases. This review discusses the properties, characterization, profiling, and the diverse molecular mechanisms of circRNAs and their use as potential therapeutic targets in different human malignancies.Entities:
Keywords: RNA binding protein; circRNA; drug resistance; miRNA sponges; signaling pathways; tumor
Year: 2021 PMID: 33614648 PMCID: PMC7894079 DOI: 10.3389/fcell.2021.617281
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X